4//SEC Filing
Graham Michelle 4
Accession 0001209191-23-014763
CIK 0001322505other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 4:52 PM ET
Size
18.1 KB
Accession
0001209191-23-014763
Insider Transaction Report
Form 4
Graham Michelle
Chief Human Resources Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2023-03-02−23,700→ 0 totalExercise: $34.88Exp: 2031-01-20→ Common Stock (23,700 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-03-02−31,500→ 0 totalExercise: $24.67Exp: 2030-01-20→ Common Stock (31,500 underlying) - Disposition from Tender
Common Stock
2023-03-02−5,543→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2023-03-02−37,500→ 0 totalExercise: $19.32Exp: 2029-11-03→ Common Stock (37,500 underlying) - Disposition to Issuer
Restricted Stock Units
2023-03-02−50,950→ 0 total→ Common Stock (50,950 underlying)
Footnotes (7)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was canceled and converted into the right to receive $42.00 in cash, without interest (the "Closing Amount")
- [F2](Continued from Footnote 2) plus one non-tradeable contractual contingent value right ("CVR" and each CVR together with the Closing Amount, the "Offer Price"), which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement (the "CVR Agreement") on or prior to December 31, 2027 (the "Milestone").
- [F3]Upon the terms and subject to the conditions set forth in the Merger Agreement, (a) each outstanding option to purchase Shares (each, a "Company Option") that was granted prior to the date of the Merger Agreement with an exercise price per Share less than $42.00 (each, an "In the Money Option"), was canceled and converted into the right to receive (A) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time multiplied by (y) the excess of (I) $42.00 over (II) the exercise price payable per Share under such In the Money Option and (B) one CVR for each Share subject to such In the Money Option immediately prior to the Effective Time; (b) each Company Option that was granted prior to the date of the Merger Agreement with an exercise price per Share equal to or greater than $42.00 but less than $52.00 (each, an "Out of the Money Option")
- [F4](Continued from Footnote 3) was canceled and converted into the right to receive, if the Milestone is achieved, cash in an amount equal to the product of (A) the total number of Shares subject to such Out of the Money Option immediately prior to the Effective Time multiplied by (B) the excess of (x) $52.00 over (y) the exercise price payable per-Share under such Out of the Money Option; and (c) each Company Option (A) that was granted on or after the date of the Merger Agreement or (B) having an exercise price per Share that is equal to or greater than $52.00 was cancelled without consideration, and had no further force or effect.
- [F5]Each restricted stock unit represents a contingent right to receive one Share.
- [F6]Pursuant to the terms of the Merger Agreement, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one CVR for each Share subject to such Company RSU immediately prior to the Effective Time; and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect.
- [F7]Not applicable.
Documents
Issuer
ALBIREO PHARMA, INC.
CIK 0001322505
Entity typeother
Related Parties
1- filerCIK 0001506315
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 4:52 PM ET
- Size
- 18.1 KB